Previous 10 | Next 10 |
2023-08-02 16:12:02 ET Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $1.31 (+47.2% Y/Y) and the consensus Revenue Estimate is $306.66M (+37.1% Y/Y). Over the last 2 year...
2023-08-01 00:23:22 ET Summary POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study of PNT2002 provide optimism for successful results...
BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023, to discuss its financial and operating results for the second qua...
2023-06-18 03:54:38 ET Summary Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes it likely that Lantheus' stock outperforms ove...
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, ann...
2023-06-03 09:45:00 ET Shares of Nano-X Imaging (NASDAQ: NNOX) are up more than 135% to start the year after the company got approval in April from the Food and Drug Administration (FDA) for its Nanox.ARC system. It may be too late to benefit from the stock's rise, but GE HealthCa...
BEDFORD, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disea...
2023-05-04 19:06:17 ET Lantheus Holdings, Inc. (LNTH) Q1 2023 Results Conference Call May 4, 2023 08:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob ...
2023-05-04 15:43:07 ET Summary Today, we circle back on Lantheus Holdings, Inc., a midcap radiology diagnostic company that is turning into a sales growth juggernaut. The company reported stellar quarterly results once again this morning for Q1 2023 and raised guidance significant...
2023-05-04 14:10:47 ET Lantheus ( NASDAQ: LNTH ) surges 15% on better-than-expected Q1 results, driven by PSMA PET with Pylarify and Definity's increasing utilization for diagnostic purposes. The company expects Q2 FY 2023 revenue to be between $300M to $310M, beating the ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.4%Change Percent:
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...